CY1123398T1 - Συνθεση συνδυασμου - Google Patents

Συνθεση συνδυασμου

Info

Publication number
CY1123398T1
CY1123398T1 CY20191100766T CY191100766T CY1123398T1 CY 1123398 T1 CY1123398 T1 CY 1123398T1 CY 20191100766 T CY20191100766 T CY 20191100766T CY 191100766 T CY191100766 T CY 191100766T CY 1123398 T1 CY1123398 T1 CY 1123398T1
Authority
CY
Cyprus
Prior art keywords
combination composition
paracetamol
ibuprofen
composition
approximately
Prior art date
Application number
CY20191100766T
Other languages
Greek (el)
English (en)
Inventor
Hartley Campbell Atkinson
Original Assignee
Aft Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123398(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aft Pharmaceuticals Limited filed Critical Aft Pharmaceuticals Limited
Publication of CY1123398T1 publication Critical patent/CY1123398T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
CY20191100766T 2010-11-04 2019-07-18 Συνθεση συνδυασμου CY1123398T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04
PCT/NZ2011/000226 WO2012060719A1 (en) 2010-11-04 2011-10-26 A combination composition

Publications (1)

Publication Number Publication Date
CY1123398T1 true CY1123398T1 (el) 2021-10-29

Family

ID=46024668

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100766T CY1123398T1 (el) 2010-11-04 2019-07-18 Συνθεση συνδυασμου

Country Status (28)

Country Link
US (6) US20130225685A1 (https=)
EP (1) EP2635269B1 (https=)
JP (2) JP2013541583A (https=)
KR (1) KR101900520B1 (https=)
CN (2) CN103298464A (https=)
AU (1) AU2011324137B2 (https=)
BR (1) BR112013010829B8 (https=)
CA (1) CA2814057C (https=)
CL (1) CL2013001250A1 (https=)
CO (1) CO6771406A2 (https=)
CY (1) CY1123398T1 (https=)
DK (1) DK2635269T3 (https=)
ES (1) ES2742373T3 (https=)
HR (1) HRP20191489T1 (https=)
HU (1) HUE045442T2 (https=)
LT (1) LT2635269T (https=)
MX (2) MX2013005113A (https=)
MY (1) MY160572A (https=)
NZ (1) NZ609727A (https=)
PH (2) PH12013500689A1 (https=)
PL (1) PL2635269T3 (https=)
PT (1) PT2635269T (https=)
RS (1) RS59258B1 (https=)
RU (2) RU2707089C2 (https=)
SG (1) SG189319A1 (https=)
SI (1) SI2635269T1 (https=)
SM (1) SMT201900481T1 (https=)
WO (1) WO2012060719A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130225685A1 (en) 2010-11-04 2013-08-29 Aft Pharmaceuticals Limited Combination composition
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
KR20170066549A (ko) * 2014-10-06 2017-06-14 큠버랜드 파마슈티컬즈 인코포레이티드 통증 치료를 위한 이부프로펜과 아세트아미노펜의 공동 정맥 투여
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
CN114681324B (zh) * 2017-07-10 2024-05-03 盖尔凯普科技有限公司 双释放剂型胶囊及其制备方法、装置和系统
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol
IL324832A (en) 2023-06-02 2026-01-01 Ioulia Tseti Pharmaceutical composition comprising ibuprofen
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
DE60114249T2 (de) * 2001-11-02 2006-05-18 Cumberland Pharmaceuticals Inc., Nashville Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure
CN1758904A (zh) * 2003-03-21 2006-04-12 麦克内尔-Ppc股份有限公司 非甾体抗炎药物的给药方案
ATE543491T1 (de) * 2004-07-07 2012-02-15 Aft Pharmaceuticals Ltd Kombinationspräparat enthaltend ibuprofen und paracetamol
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
CA2666582C (en) * 2006-10-20 2014-09-09 Mcneil-Ppc, Inc. Acetaminophen / ibuprofen combinations
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
US20110166234A1 (en) * 2008-10-14 2011-07-07 Atkinson Hartley Campbell Medicinal product and treatment
KR20140014350A (ko) * 2009-03-12 2014-02-06 큠버랜드 파마슈티컬즈 인코포레이티드 정맥 내 투여용 이부프로펜의 투여
SG186388A1 (en) * 2010-07-07 2013-01-30 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
US20130225685A1 (en) 2010-11-04 2013-08-29 Aft Pharmaceuticals Limited Combination composition
KR20170066549A (ko) * 2014-10-06 2017-06-14 큠버랜드 파마슈티컬즈 인코포레이티드 통증 치료를 위한 이부프로펜과 아세트아미노펜의 공동 정맥 투여

Also Published As

Publication number Publication date
BR112013010829A2 (pt) 2016-08-16
US20190029982A1 (en) 2019-01-31
KR101900520B1 (ko) 2018-09-19
RU2015103107A (ru) 2015-06-20
SI2635269T1 (sl) 2019-10-30
US20250134839A1 (en) 2025-05-01
EP2635269A1 (en) 2013-09-11
CN107519159A (zh) 2017-12-29
US20160235695A1 (en) 2016-08-18
RU2015103107A3 (https=) 2018-08-20
CL2013001250A1 (es) 2013-08-30
BR112013010829B8 (pt) 2022-01-04
RU2707089C2 (ru) 2019-11-22
PT2635269T (pt) 2019-09-04
DK2635269T3 (da) 2019-08-26
CO6771406A2 (es) 2013-10-15
LT2635269T (lt) 2019-09-10
US11896567B2 (en) 2024-02-13
NZ609727A (en) 2015-07-31
RU2013123646A (ru) 2014-12-10
SMT201900481T1 (it) 2019-11-13
HUE045442T2 (hu) 2019-12-30
MX367209B (es) 2019-07-22
JP2017132791A (ja) 2017-08-03
AU2011324137A1 (en) 2013-05-02
US12220392B2 (en) 2025-02-11
HRP20191489T1 (hr) 2019-11-15
JP2013541583A (ja) 2013-11-14
MY160572A (en) 2017-03-15
PH12013500689A1 (en) 2013-05-27
WO2012060719A1 (en) 2012-05-10
AU2011324137B2 (en) 2015-05-07
MX2013005113A (es) 2013-06-03
RS59258B1 (sr) 2019-10-31
EP2635269B1 (en) 2019-05-22
JP6353577B2 (ja) 2018-07-04
BR112013010829B1 (pt) 2021-12-21
PL2635269T3 (pl) 2019-11-29
US20230000805A1 (en) 2023-01-05
CN103298464A (zh) 2013-09-11
SG189319A1 (en) 2013-05-31
KR20140025314A (ko) 2014-03-04
US11446266B2 (en) 2022-09-20
US20130225685A1 (en) 2013-08-29
ES2742373T3 (es) 2020-02-14
CA2814057C (en) 2022-02-01
US20240207210A1 (en) 2024-06-27
PH12021550804A1 (en) 2022-02-14
CA2814057A1 (en) 2012-05-10
EP2635269A4 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
CY1123398T1 (el) Συνθεση συνδυασμου
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1116727T1 (el) Θεραπεια πολλαπλης σκληρυνσης me laquinimod
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
CY1121735T1 (el) 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου
CY1121646T1 (el) Παραγωγα μορφινανης για την αγωγη υπερβολικης δοσης ναρκωτικων
MX2013007189A (es) Metodos y composiciones adecuados para manejar glucosa en sangre en animales.
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1118680T1 (el) Φαρμακευτικη συνθεση
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
CY1114988T1 (el) Βενζοδιαζεπινη αναστολεας bromodomain
UY34358A (es) ?tratamiento de la esclerosis múltiple con una combinación de laquinimod y acetato de glatiramer?.
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
PH12014500386A1 (en) Combination treatment for hepatitis c
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
CY1121628T1 (el) 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης
AR082312A1 (es) Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos
CY1122198T1 (el) Ιατρικο προϊον και θεραπεια
PA8784901A1 (es) Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial